• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Gagelmann, N.
    Sureda, A.
    Montoto, S.
    Murray, John
    Bolaños, N.
    Kenyon, M.
    Beksac, M.
    Schönland, S.
    Hayden, P.
    Scheurer, H.
    Morgan, K.
    Garderet, L.
    McLornan, D. P.
    Ruggeri, A.
    Show allShow less
    Affiliation
    University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care-a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma.
    Citation
    Gagelmann N, Sureda A, Montoto S, Murray J, Bolaños N, Kenyon M, et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. The Lancet Haematology. 2022 Oct;9(10):e786-e95. PubMed PMID: 36174641. Epub 2022/09/30. eng.
    Journal
    Lancet Haematology
    URI
    http://hdl.handle.net/10541/625695
    DOI
    10.1016/s2352-3026(22)00226-5
    PubMed ID
    36174641
    Additional Links
    https://dx.doi.org/10.1016/s2352-3026(22)00226-5
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/s2352-3026(22)00226-5
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
    • Authors: Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I
    • Issue date: 2022 Mar
    • Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    • Authors: Marofi F, Tahmasebi S, Rahman HS, Kaigorodov D, Markov A, Yumashev AV, Shomali N, Chartrand MS, Pathak Y, Mohammed RN, Jarahian M, Motavalli R, Motavalli Khiavi F
    • Issue date: 2021 Mar 29
    • The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
    • Authors: Feinberg D, Paul B, Kang Y
    • Issue date: 2019 Nov
    • Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
    • Authors: Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H
    • Issue date: 2019 Dec
    • Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
    • Authors: Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, Hamadani M, McGuirk J, Shune L
    • Issue date: 2022 Jul
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.